Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that robust growth is predicted for the unstable angina drug market. A new Pharmacor report from Decision Resources, Unstable Angina, forecasts that the market for unstable angina/non-ST- elevation myocardial infarction (UA/NSTEMI) therapies will grow at a rate of 7.9% per year over the 2001-2011 forecast period. Increased use of gpIIb/IIIa inhibitor therapies such as Integrilin (eptifibatide) from Schering-Plough and Aggrastat (tirofiban) from Merck will drive the market.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"Incorporation of early invasive and aggressive treatment strategies worldwide will increase sales of gpIIb/IIIa inhibitors by 40% from 2001 to 2011," said Nicola Maidwell, Ph.D., analyst at Decision Resources. "And even more opportunity exists for companies with novel anticoagulation therapies and for those developing other novel approaches to treating UA/NSTEMI."

Disease Facts -- Unstable Angina

Unstable angina/non-ST-elevation myocardial infarction is the most common manifestation of coronary artery disease. UA/NSTEMI is associated with significant morbidity and mortality -- an 8-15% incidence of death or subsequent nonfatal NSTEMI and ST-elevation myocardial infarction (STEMI) at 30 days and a 10-20% incidence at six months. Introductions of new therapies over the past five years have improved mortality and morbidity rates, but there is wide geographical variation in the utilization of these therapies in the treatment of UA/NSTEMI. Such variation provides opportunity for extended use of current therapies in select major pharmaceutical markets.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Unstable Angina is a Cardium report.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.decisionresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44774880

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Disease Susceptibility Testing Accounts for One-Third of the Total Post- Genomics Diagnostics Market

View Now